Paragon Advisors LLC Sells 1,740 Shares of Eli Lilly and Company $LLY

Paragon Advisors LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 27.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,707 shares of the company’s stock after selling 1,740 shares during the period. Paragon Advisors LLC’s holdings in Eli Lilly and Company were worth $3,591,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Brighton Jones LLC boosted its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the last quarter. OneAscent Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 32.0% in the second quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after buying an additional 87 shares in the last quarter. Patton Fund Management Inc. bought a new position in shares of Eli Lilly and Company during the second quarter worth $211,000. Finally, Trivium Point Advisory LLC boosted its position in shares of Eli Lilly and Company by 3.2% during the second quarter. Trivium Point Advisory LLC now owns 2,966 shares of the company’s stock worth $2,312,000 after acquiring an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.5%

Shares of NYSE:LLY opened at $1,024.14 on Thursday. The company has a market cap of $968.20 billion, a price-to-earnings ratio of 50.10, a PEG ratio of 0.79 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a 50-day moving average price of $1,057.65 and a 200 day moving average price of $886.06.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.18 earnings per share. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 29.35%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a research report on Monday, November 10th. Truist Financial lifted their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. Wolfe Research increased their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Finally, The Goldman Sachs Group raised their price target on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 15th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $1,173.91.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Signed a potential $1.93 billion deal with Repertoire to develop autoimmune therapies — expands Lilly’s immune‑disease pipeline and adds milestone/licensing upside that could underpin future revenue growth and valuation. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: Entered a deal (up to ~$1.12B) with Seamless Therapeutics to develop gene‑editing treatments for hearing loss — adds high‑value, high‑optionality programs and gives Lilly exposure to novel recombinase technology. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: Oncology and AI catalysts: coverage highlights Lilly’s oncology pipeline plus a ~$1B AI collaboration with Nvidia to speed drug discovery — could accelerate new launches and support mid‑term revenue growth. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Positive Sentiment: Analyst/earnings setup looks favorable: earnings‑surprise history and consensus expectations point to another likely beat, supporting near‑term sentiment around fundamentals. Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Positive investor writeups and “top picks” pieces argue for multi‑year growth driven by GLP‑1 leadership and pipeline, but these are opinion pieces that may already be priced in. Top Picks 2026: Eli Lilly & Co.
• Negative Sentiment: Medicare drug price negotiation named a Lilly Part B product (Verzenio) for talks — introduces downside risk to pricing and margins if negotiated cuts apply to key products. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Competitive pressure: Reuters data shows Novo Nordisk doubled U.S. ad spend vs. Lilly for GLP‑1s — implies intensified market share battle and potentially higher marketing costs or share erosion. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Market reaction note: coverage points out shares fell even after the gene‑editing tie‑ups, signaling investor concerns about valuation, near‑term growth execution, or policy/competitive risks despite the deals. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.